Abstract
Clozapine has been recently FDA approved and is expected to become very popular because of its efficacy and lack of extrapyramidal side effects. The neuroleptic malignant syndrome (NMS) has already been reported in two cases associated with clozapine use. In this article, we present a case in which a patient receiving clozapine monotherapy developed a complex of symptoms that appeared to be NMS without rigidity. The case meets specific criteria for NMS and the absence of rigidity may be attributable to the anatomic selectivity of clozapine's dopamine blockade.